Please login to the form below

Not currently logged in

Helen Parfitt joins Research Partnership

She takes on role as head of its Therapy Watch market tracking tool

Helen ParfittResearch Partnership has appointed Helen Parfitt as its new director, head of Therapy Watch - a ‘real-time’ syndicated global market tracking tool - in a role that will see her based at the firm’s head office in London.

Prior to joining the company, Parfitt has previously worked for IMS Health (now QuintilesIMS) as its director of core data assets, global technology services and operations, and subsequently as commercial director for M3 Group’s European division.

Her new role will see her join research directors Julia Godfrey and Laurent Chanroux in supporting the continued expansion of Therapy Watch, which currently runs global monitors in auto-immune, virology, oncology and nephrology.

She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its coverage.

Mark Jeffery, founding director of Research Partnership, said: “Helen brings with her a wealth of knowledge and expertise, her experience at GSK and Schering-Plough means she has also developed a strong understanding of clients’ needs.

“I believe she will be a strong asset to the Therapy Watch team and we look forward to her contributing to its continued growth and development.”

8th May 2017

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...